Mustang Bio inks agreement with Netherlands' Leiden University

By The Science Advisory Board staff writers

November 10, 2021 -- Mustang Bio has entered into an exclusive licensing agreement with Leiden University Medical Center in Leiden, the Netherlands, for an ex vivo lentiviral gene therapy for the treatment of recombination activating 1 severe combined immunodeficiency.

The therapy is being assessed in a phase I/II European clinical trial. Mustang Bio is working with Frank Staal, PhD, whose laboratory at the university developed the therapy, the company said. Staal will continue to develop other lentiviral gene therapies, and Mustang Bio will have licensing rights to them as well.

If you like this content, please share it with a colleague!

Related Reading

Mustang Bio, Mayo Clinic partner on viral CAR T technology
Mustang Bio announced it is collaborating with the Mayo Clinic on a novel technology for CAR T-cell therapies.

Regulatory Roundup: antibodies, immunotherapies, expanded flu treatment use
Welcome to this week's edition of Regulatory Roundup. This past week, several novel therapies for the treatment of rare diseases and cancers have received...

Minaris to manufacture Mustang Bio's lentiviral gene therapy in Europe
Minaris Regenerative Medicine has signed an agreement with Mustang Bio to enable technology transfer and good manufacturing practice clinical manufacturing...